Pharmacodynamics: Mechanism of Action and Effects
The primary action of oxytocin is targeted at smooth muscle tissue. First and foremost, it stimulates the contractility of the myometrium, exerting the greatest effect on the body of the uterus. Notably, the responsiveness of the smooth muscle cells is dynamic and closely tied to the patient's hormonal milieu and gestational age. While the non-pregnant uterus is virtually unresponsive to the hormone, the density of oxytocin receptors increases progressively during gestation, reaching an absolute maximum directly at the onset of labor.
In addition to its effects on the reproductive system, the drug plays a key role in lactation through two distinct mechanisms:
- Central effect: Acts on the anterior pituitary gland to stimulate prolactin release, enhancing milk synthesis.
- Peripheral effect: Causes contraction of the myoepithelial cells surrounding the mammary gland ducts, thereby facilitating milk ejection (let-down reflex).
Pharmacokinetics and Route of Administration
Upon entering systemic circulation, oxytocin molecules do not bind significantly to plasma proteins. The active substance has an extremely short half-life ($t_{1/2}$), ranging from 1 to 4 minutes.
The onset of clinical effect and its duration depend directly on the route of administration:
- Intravenous administration (often administered as an infusion diluted in a glucose solution) has a rapid onset, typically within 30 to 60 seconds.
- Intramuscular injection has a delayed onset of 3 to 7 minutes, but its duration is extended, ranging from 30 minutes to 3 hours.
Clinical Application in Obstetrics
Preparations in this group are dosed in international units (IU) and are used in strictly defined clinical scenarios:
- Labor induction and augmentation. The primary indication is diagnosed uterine inertia (hypotonic labor dysfunction).
- Management of the postpartum period. Uterotonics are essential for the prophylaxis and emergency treatment of postpartum hemorrhage due to uterine atony. Increasing myometrial tone promotes rapid uterine involution.
- Support of breastfeeding. For impaired milk ejection, intranasal formulations (sprays) are administered 2–3 minutes before nursing.
Safety Profile and Limitations
The use of uterine stimulants carries significant maternal and fetal risks. Cardiovascular effects can include blood pressure fluctuations, arrhythmias, and fetal bradycardia, and rarely, hypotension and shock. Severe obstetric complications include uterine hyperstimulation (tetany) and placental abruption. Hypersensitivity reactions, bronchospasm, nausea, and vomiting may also occur. If any such symptoms are observed, the infusion must be stopped immediately.
Absolute Contraindications:
- Mechanical obstruction to spontaneous vaginal delivery (cephalopelvic disproportion, face presentation, transverse or oblique lie).
- Uterine scarring (history of classical cesarean section or major cervical/uterine surgery).
- Severe maternal systemic pathology (severe renal impairment, uncontrolled hypertension).
Analogs and Animal-Derived Preparations
In addition to synthetic oxytocin, clinicians have access to other agents with similar mechanisms of action:
- Demoxytocin (desaminooxytocin). A synthetic analog that surpasses the native hormone in certain aspects of pharmacological activity. Its main advantage is resistance to salivary enzymes. It is available as buccal tablets, which are efficiently absorbed through the oral mucosa. It is used for uterine inertia, to accelerate uterine involution, and to stimulate lactation.
- Pituitrin. An aqueous extract of the posterior pituitary gland obtained from livestock. It contains both oxytocin and vasopressin (antidiuretic hormone). Due to the presence of vasopressin, the drug has a notable vasopressor side effect, potentially raising blood pressure.
- Hyphotocin. Another animal-derived extract, but unlike pituitrin, it contains predominantly oxytocin, making its hemodynamic effects more selective.